Improving cancer treatment access for patients in Nigeria
Official title: Addressing cancer disparities in Nigeria through Immuno-oncology Research – The NOLA Program
Funded at Sloan-Kettering Inst Can Research · NIH-10879522 · Data updated 2026-11-12
This study is looking to improve colorectal cancer treatment for patients in Nigeria by exploring how certain biological factors affect their care, and it aims to start the first trial of immunotherapy for this type of cancer in sub-Saharan Africa, helping to find out which patients might benefit the most from this new treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 16, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $383,091 |
| NIH project number | 1P20CA290448-01 |
| Project ID | NIH-10879522 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are Nigerian patients diagnosed with colorectal cancer, particularly those exhibiting the MSI-H phenotype.
✕Less likely to help
Patients with colorectal cancer who do not have access to the study or do not meet the specific biological criteria may not benefit from this research.
What this research studies
This research focuses on addressing the significant disparities in colorectal cancer treatment for patients in Nigeria, where immunotherapy is not widely available. By investigating the biological factors that contribute to these disparities, particularly the higher rates of a specific cancer phenotype in Nigerian patients, the research aims to initiate the first prospective trial of immunotherapy for colorectal cancer in sub-Saharan Africa. The study will also work on developing biomarkers to identify patients who are most likely to benefit from this treatment, ensuring a more effective and tailored approach to cancer care.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for colorectal cancer patients in Nigeria.
How similar studies have gone: Previous research has shown promise in using immunotherapy for colorectal cancer in other populations, but this approach in Nigeria is novel and untested.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Kingham, T Peter — Sloan-Kettering Inst Can Research
- Study coordinator: Kingham, T Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.